Da-Cheng-Qi decoction (DCQD) is a purgative compound prescription used in China and East Asia. In this paper, pharmacokinetic differences of six major active components (rhein, emodin, aloe-emodin, magnolol, naringenin and hesperetin) between DCQD and its three constitutional herbal medicines i.e. Radix et Rhizoma Rhei, Cortex Magnoliae officinalis and Fructus Aurantii Immaturus were investigated in rats after oral administration. Plasma samples were analyzed for the quantification of the six active components using validated LC-MS/MS methods. Unpaired Student's t-test was used for statistical comparison. Significant differences (p<0.05) in the main pharmacokinetic parameters for rhein, emodin, aloeemodin, magnolol, naringenin and hesperetin were found between DCQD and the decoction of its constitutional single herbal medicines, which demonstrated the presence of drug-drug interactions between these constitutional raw materials of DCQD occurring either in the procedure of decoction or during ADME process.
Described in Shang-Han-Lun (Treatise on Cold damage Diseases, a Chinese medicine classic from the Han dynasty), Da-Cheng-Qi decoction (DCQD) is a well known purgative formula consisting of four natural medicines i.e. Radix et Rhizoma Rhei (Dahuang), Cortex Magnoliae officinalis (Houpu), Fructus Aurantii Immaturus (Zhishi) and Natrii Sulfas (Mangxiao) [1] . Nowadays, DCQD is usually used to treat diseases such as acute intestinal obstruction without complications, acute cholecystitis and appendicitis [2] . DCQD is also used in treating posttraumatic respiratory distress syndrome [3] , reducing acute-phase protein levels in patients with multiple organ failure syndromes [4] , and relieving inflammation in patients after a tumor operation [5] . Recently, DCQD was found to possess anti-inflammatory effects apart from its purgative activities [6] .
Pharmacokinetics is an important method to determine the fate of substances in living organisms. Due to the complexity of chemicals in compound prescriptions of traditional Chinese medicines (TCMs), the pharmacokinetics of one ingredient in the compound prescription is usually studied to present the pharmacokinetics of the whole prescription. However, herb-herb and herb-compounds pharmacokinetic interaction investigations of a compound prescription have been far less investigated, although these might be very important to explain the pharmacological foundation for the mechanism of action and compatibility of compound prescriptions.
Up to now, little study has been performed on the pharmacokinetics of DCQD. Aloe-emodin and chrysophanol were selected as markers to examine the pharmacokinetics of DCQD using an HPLC-UV method [7] . The difference in the pharmacokinetics of rhein in rats after oral administration of DCQD and Xiao-Cheng-Qi decoction (XCQD) has also investigated [8] . However, there is no report about the pharmacokinetic differences between DCQD and its three constitutional herbal medicines, and thus the aim of this work was to fill this gap.
In order to obtain a more intuitional impression of the pharmacokinetic differences in the six bioactive components between DCQD and its constitutional herbal medicines, the term of relative bioavailability (F, %) was introduced, which could be calculated using the following equation: F (%)= (AUC single herbal medicines / AUC DCQD )×100%.
Rhein, emodin and aloe-emodin are representative active anthraquinones found in Radix et Rhizoma Rhei. Figure 1 shows the mean plasma concentration-time profiles of rhein, emodin and aloe-emodin in rats after oral administration of DCQD and a single Radix et Rhizoma Rhei decoction. The main pharmacokinetic parameters of these three anthraquinones are summarized in Table 1 . Compared with DCQD, when the Radix et Rhizoma Rhei decoction was orally administrated to rats, these three anthraquinones showed the same pharmacokinetic trend: decreased C max , increased AUC 0-∞ , and delayed elimination rate (t 1/2 ). The relative bioavailability (F AUC0-∞, %) of rhein, emodin and aloe-emodin was 169.0, 113.2 and 221.8, respectively. The results for F AUC0-∞ and F AUC0-t, for emodin and aloe-emodin did not match very well, which might result from the insufficiency of the number of assay time points in the elimination phase. The concentration of rhein was much higher than that of emodin and aloe-emodin, which might be because of the higher content in the extract or/and the metabolic biotransformation between anthraquinone derivatives [9] . The results of the pharmacokinetic comparison of rhein, emodin and aloe-emodin between the two groups, i.e. DCQD and single Radix et Rhizoma Rhei decoction, indicated that there might be some drug-drug interaction between Radix et Rhizoma Rhei and the other 3 constitutional raw materials in DCQD in the procedure of decoction or/and ADME, which could increase the plasma concentration, but decrease the bioavailability, and accelerate the elimination rate of these three anthraquinones.
Cortex Magnoliae officinalis is a known source of lignans, among which magnolol is important and usually adopted as a marker to evaluate the quality of the drug. Plasma concentration-time profiles of magnolol in rats after oral administration of DCQD and Cortex Magnoliae officinalis decoction are shown in Figure 2 , while Table 2 summarizes the main pharmacokinetic parameters. When compared with the group of DCQD that of Cortex Magnoliae officinalis decoction shows the following pharmacokinetic prosperities: decreased C max and AUC. The relative Our previous study showed that the concentrations of hesperidin and naringin were much higher than those of their corresponding flavanone aglycones (hesperetin and naringenin) in DCQD [10] . However, when DCQD was orally administrated to rats, the plasma concentrations of hesperidin and naringin were too low to be detected while those of hesperetin and naringenin were high enough for pharmacokinetic study. This phenomenon was proposed as the result of the hydrolysis of hesperidin and naringin mediated by gastrointestinal bacteria [11, 12] . The plasma concentration-time profiles of naringenin and hesperetin in rats after oral administration of DCQD and single Fructus Aurantii Immaturus decoction present obvious bimodal phenomena ( Figure. 3), which might be the result of the double-site absorption and interbiotransformation of hesperidin and naringin with their flavanone aglycones, hesperetin and naringenin, respectively. Compared with DCQD, when single Fructus Aurantii Immaturus decoction was orally administrated to rats, naringenin and hesperetin both showed the same pharmacokinetic trend (Table 3) : increased C max 1 and AUC, but decreased C max 2 . The relative bioavailability (F AUC0-∞ , %) of naringenin and hesperetin were 140.4 and 185.9, respectively. No statistical significance was found for T max 1 , T max 2 and T 1/2 . The above findings demonstrated that the three constitutional raw materials in DCQD might influence the extent of absorbtion of naringenin and hesperetin, but not their absorption and elimination rates.
In summary, our studies show that there are statistically significant differences in the main pharmacokinetic parameters of rhein, emodin, aloe-emodin, magnolol, naringenin and hesperetin between DCQD and its constitutional herbs when orally administered to rats. These differences might result from drug-drug interactions between the four constitutional raw materials in DCQD, either in the procedure of decoction or during the ADME process. In order to clarify the exact sources of the factors leading to these pharmacokinetic differences, further studies will be conducted to combine extractive rates and 
Preparation of Da-Cheng-Qi decoction and single natural medicines decoction:
The DCQD was prepared according to the method and procedure described in Shang-Han-Lun and was optimized [10, 11, 13, 14] : the bark of Cortex Magnoliae officinalis (24 g) and Fructus Aurantii Immaturus (15 g ) were immersed in 300 mL distilled water and boiled until half of the original amount was left. This procedure was repeated. The two water extracts were combined. Radix et Rhizoma Rhei (12 g) were then immersed in the above mentioned combined water extracts and boiled until half of the original amount was left, and then Natrii Sulfas (6 g) was dissolved in the water extract. The extract was then filtered, diluted to 250 mL with distilled water, and stored at 4 o C until use. Single herb decoction (positive control) and single natural medicine free decoction (negative control) were also prepared according to the above preparation procedure for DCQD, but without the three raw drugs.
Animals, drug administration and plasma collection:
Six Sprague-Dawley rats (3 male and 3 female; body weight, 190 ± 10 g) were supplied by the Animal Multiplication Center of Qinglong Mountain (SCXK 2007-0007). The experimental protocol was approved by the University Ethics Committee for the use of experimental animals and conformed to the Guide for Care and Use of Laboratory Animals. The rats were maintained in air-conditioned animal quarters under the following conditions: temperature 22 ± 2°C, relative humidity 55 ± 10%, free access to water, and feeding with laboratory rodent chow (Nanjing, China). The animals were acclimatized to the facilities for 10 days and were then fasted with free access to water for 12 h prior to the experiment. Blood samples (0.5 mL) were collected at time points of 0 (prior to administration), 0.083, 0.166, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 h after a single dose. The rats were intragastric administrated with 2 mL of water at the time points of 0.5 h, 4 h and 12 h, respectively. The rats had free access to water during the experiment. The blood samples were immediately heparinized and centrifuged at 7885 g for 5 min, and the supernatant was harvested into 0.2 mL aliquots and stored in 1.5 mL polypropylene tubes at −4°C prior to analysis.
Samples preparation:
For quantitative analysis, an aliquot (0.2 mL) of rat plasma was pipetted into 1.5 mL plastic centrifuge tubes with addition of 500 μL methanol (containing 0.1% formic acid and IS) to precipitate protein. Then the samples were vortex mixed for 3 min and centrifuged at 13800 g for 8 min. The upper layer was transferred into another 1.5 mL plastic centrifuge tube and centrifuged at 13800 g for a further 8 min. Ten μL aliquots of the supernatant were injected into the LC-MS/MS system.
Analytical method and validation:
The assay of the 6 markers in rat plasma have been developed and validated in our previous reports [11, 13] . Liquid chromatographic separation and MS detection were achieved by employing the Finnigan TM TSQ Quantum Discovery MAXTM LC-MS/MS system, which consisted of a Finnigan Surveyor LC pump, a Finnigan Surveyor auto-sampler and combined with a triple quadrupole TSQ Quantum mass spectrometer (Thermo Electron Corporation). The tandem MS system was equipped with an ESI and APCI source, and run with the Xcalibur 2.0 software (Thermo Electron Corporation).
Naringenin and hesperetin were separated on a Zorbax SB-C18 (150 mm × 3.0 mm, 3.5μm) analytical column at 40°C. The isocratic mobile phase was a mixture of 0.1% formic acid/methanol (45/55, v/v), which was pumped at a flow rate of 0.4 mL/min. The tandem MS system was equipped with an APCI source. The mass spectrometer was operated in positive ion and SRM modes with precursor to product qualifier transition m/z 273→153 for naringenin, m/z 303→153 for hesperetin and m/z 295→205 for estazolam (IS). The mass spectrometric conditions were optimized in order to achieve maximum sensitivity: discharge voltage 6.0V, heated capillary temperature 275°C, sheath gas and auxiliary gas (nitrogen) pressure 37 and 15 arbitrary unites (set by the LCQ software, Thermo Electron Corporation), respectively. Argon was used as collision gas at a pressure of 1.5 mTorr and collision energy was 25V for naringenin, hesperetin and estazolam. The scan width for SRM was 0.01 m/z, and scan time was 0.3 s. The peak width settings (FWHM) for both Q1 and Q3 were 0.7 m/z [11] .
Magnolol, rhein, emodin and aloe emodin were separated on a Zorbax SB-C 18 (100 mm × 3.0 mm, 3.5 μm) analytical column at 45°C. The isocratic mobile phase was a mixture of 0.1% formic acid/methanol (30/70, v/v), which was pumped at a flow rate of 0.4 mL/min. The tandem MS system was equipped with an ESI source. The mass spectrometer was operated in negative ion and SRM modes with precursor to product qualifier transition m/z 265.0→247.0 for magnolol, m/z 283.0→238.9 for rhein, m/z 268.9→224.9 for emodin, m/z 269.0→239.9 for aloe emodin and m/z 526.0→400.9 for gliquidone (IS). The mass spectrometric conditions were optimized in order to achieve maximum sensitivity: spray voltage -4000V, heated capillary temperature 350°C, sheath gas and auxiliary gas (nitrogen) pressure 45 and 25 arbitrary unites (set by the LCQ software, Thermo Electron Corporation), respectively. Argon was used as collision gas at a pressure of 1.5 mTorr and collision energy was 23V for magnolol, 26V for honokiol, 15V for rhein, 30V for emodin and 25V for aloe-emodin. The scan width for SRM was 0.01 m/z and scan time was 0.3s. The peak width settings (FWHM) for both Q 1 and Q 3 were 0.7 m/z [13] .
